Contract HHSO100201500022C

First Light Diagnostics, Inc. · Department Of Health And Human Services · September 29, 2020

Cost Plus Fixed FeeFull & Open CompetitionNAICS 325413

First Light Diagnostics, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 29, 2020 for $4.79 million of work in in-vitro diagnostic substance manufacturing. Performance is in Chelmsford, MA. It was awarded under full and open competition. The contract has been modified 4 times since the base award It uses cost-plus contract pricing. The most recent modification was on August 12, 2025. If all options are exercised, the contract could reach $41.41 million.

Obligated to date
$4.79M
$4,791,387
Current value
$41.41M
Modifications
4
Latest August 12, 2025

Contract details

PIID
HHSO100201500022C
Award type
Definitive Contract
Pricing
Cost Plus Fixed Fee
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
325413 · In-Vitro Diagnostic Substance Manufacturing
Product / service
Health R&D Services; Health Care Services; Basic Research
Place of performance
Chelmsford, MA
First action
September 29, 2020
Latest action
August 12, 2025

Description

DE-OBLIGATE $15,438.10 AND CLOSEOUT THE CONTRACT IN ITS ENTIRETY.

Modification timeline

  • August 12, 2025
    Mod P00029 · Close Out
    $30.21M
  • September 28, 2022
    Mod P00023 · Other Administrative Action
    FIRST LIGHT DIAGNOSTICS: SUPPLEMENTAL FUNDING AND REVISE COR.
    $29.72M
  • September 27, 2021
    Mod P00017 · Funding Only Action
    ANTHRAX ASSAY R&D - RAPID, SENSITIVE AND COST-EFFECTIVE ANTHRAX TEST AND CLINICAL SURGE-TESTING PLATFORM.
    $28.54M
  • September 30, 2020
    Mod P00014 · Supplemental Agreement For Work Within Scope
    ANTHRAX ASSAY R&D - RAPID, SENSITIVE AND COST-EFFECTIVE ANTHRAX TEST AND CLINICAL SURGE-TESTING PLATFORM.
    $28.47M
  • September 29, 2020
    Mod P00013 · Exercise An Option
    ANTHRAX ASSAY R&D - RAPID, SENSITIVE AND COST-EFFECTIVE ANTHRAX TEST AND CLINICAL SURGE-TESTING PLATFORM.
    $27.88M

Similar contracts

RecipientAgencyDateObligated
Roche Diagnostics CorporationDepartment Of Health And Human ServicesApril 1, 2026$75.2K
Roche Diagnostics CorporationDepartment Of Health And Human ServicesApril 1, 2026$313.4K
Sysmex America, IncDepartment Of Health And Human ServicesMarch 31, 2026$49.2K
Becton, Dickinson And CompanyDepartment Of Health And Human ServicesMarch 31, 2026$5.7K
Biomerieux IncDepartment Of Health And Human ServicesMarch 31, 2026$0
Beckman Coulter, Inc.Department Of Health And Human ServicesMarch 30, 2026$80.2K

Top contractors in NAICS 325413

Lifetime obligated dollars across all federal contracts in this NAICS code.

#ContractorContractsObligated
1Biomerieux Inc182$25.50M
2Cepheid114$20.70M
3Roche Diagnostics Corporation125$13.00M
4Quest Diagnostics Incorporated8$4.31M
5Hologic Sales And Service, Llc39$3.88M
6Beckman Coulter, Inc28$3.40M
7Fisher Scientific Company L.L.C.52$3.04M
8Werfen USA Llc91$2.75M
9Diasorin Inc21$2.74M
10Abbott Laboratories Inc.10$2.69M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract HHSO100201500022C?

Contract HHSO100201500022C is a federal contract awarded to First Light Diagnostics, Inc. by Department Of Health And Human Services on September 29, 2020 for $4.79 million of work classified under IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING. It has been modified 4 times since the base award.

Who won contract HHSO100201500022C?

First Light Diagnostics, Inc. won contract HHSO100201500022C from Department Of Health And Human Services.

How much is contract HHSO100201500022C worth?

Contract HHSO100201500022C has obligated $4.79 million to date, with a total potential value of $41.41 million if all options are exercised.